Aadi Bioscience Inc reports results for the quarter ended in June - Earnings Summary

Whitehawk Therapeutics

09/08/2023 14:32

* Aadi Bioscience Inc  AADI.OQ  reported a quarterly
adjusted loss
of 67 cents​​ per share for the quarter ended in June. The mean
expectation of five analysts for the quarter was for a loss
of 62 cents per share.
    * Revenue rose 80.4% to $6.20 million from a year ago;
analysts
expected $6.20 million. 
    * Aadi Bioscience Inc's reported EPS for the quarter was a
loss
of 67 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aadi Bioscience Inc shares had fallen by 14.6% this
quarter and
lost 54.5% so far this year.
    * The company reported a quarterly loss of $17.97 million.
    * Wall Street's median 12-month price target for Aadi
Bioscience
Inc is $33.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 9 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.62          -0.67          Missed
 Mar. 31 2023      -0.58          -0.57          Beat
 Dec. 31 2022      -0.71          -0.52          Beat
 Sep. 30 2022      -0.74          -0.68          Beat